Ms. Kiehn is a counsel in the firm’s Litigation Department, based in the New York office. Her practice focuses on healthcare-related enforcement, litigation and compliance, including in the areas of white collar and regulatory defense, government and internal investigations, general commercial litigation and compliance and regulatory advice. She has broad experience representing pharmaceutical and medical device companies, hospitals, pharmacies and individuals in a variety of healthcare-related matters, including government investigations relating to sales and marketing practices, manufacturing and distribution issues, clinical trials, healthcare program reporting and individual Park liability; False Claims Act litigation and consumer and third-party payor class actions alleging deceptive practices; and international disputes relating to drug development, manufacturing and safety. Her experience includes healthcare program exclusion matters and Corporate Integrity Agreement negotiation and implementation. She regularly advises clients—including major pharmaceutical and device companies—on corporate compliance standards and best practices in the healthcare industry.

Ms. Kiehn is recommended by Who’s Who Legal: Global Healthcare (2021) as “an established figure in the healthcare market” who is recognized as “an expert in regulatory enforcement matters.”  She is the co-author of numerous articles, including “Medicare Advantage Plans Must Beware DOJ Scrutiny,” Law360 (January, 2022); “A Walk in the Park Shouldn't Lead to Jail Time: Recent Decisions Explain Why Incarceration is Never Appropriate for ‘Responsible Corporate Officers’ Who Lack Criminal Intent,” Bloomberg BNA’s Pharmaceutical Law & Industry Report (October, 2016); “It’s A Hard-Knock Life: The Rough-And-Tumble Fight Over Orphan Drug Pricing,” Bloomberg BNA’s Pharmaceutical Law & Industry Report (November, 2014); “DOJ Proposal Shows Focus on Individuals in Corporate Crime,” Law360 (September, 2014); “Compliance Corner: The Clock Is Ticking: 60-Day Rule and FCA Liability for Overpayments,” Bloomberg BNA’s Health Care Fraud Report (September, 2014); “Vicarious Criminal Liability in the Executive Suite for Problems on the Manufacturing Floor,” Bloomberg BNA’s Pharmaceutical Law & Industry Report (April, 2014); “GSK's $3 Billion Settlement Reflects Continued Expansion In Scope Of Pharma Plea Agreements,” Rx Compliance Report (August, 2012) and “An Unprecedented Settlement For FDCA Violation,” Law360 (May, 2012).

Ms. Kiehn joined the firm in 2001, then rejoined the firm in 2003. From 2000 to 2001, she clerked for the Hon. John S. Martin, Jr., Southern District of New York. From 2002 to 2003, she clerked for the Hon. Chester J. Straub, U.S. Court of Appeals for the Second Circuit. Ms. Kiehn received a J.D. cum laude from Fordham University School of Law in 2000. She was writing & research editor of the Fordham Law Review. Ms. Kiehn received an M.A. from New York University in 1996, and a B.A. from Smith College in 1992.

Prior to coming to the firm, Ms. Kiehn worked in the publishing field.